Hutchmed (China) Limited (HCM) ORD USD0.10
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
- Add to watchlist
- Create an alert
- This stock can be held in a
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
Share news, reports & tips
-
Hutchmed gets tazemetostat new drug application approved in China
4 July 2024 14:03
(Sharecast News) - Hutchmed China announced on Thursday that the China National Medical Products Administration (NMPA) has accepted its new drug application (NDA) for tazemetostat, granting it priority...
-
Hutchmed partner gets European approval for fruqintinib
24 June 2024 12:20
(Sharecast News) - Hutchmed China announced on Monday that its partner Takeda has received approval from the European Commission for 'Fruzaqla', or fruquintinib, as a monotherapy for adult patients...
-
Hutchmed publishes positive sovleplenib trial results
17 June 2024 09:28
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
-
Hutchmed China launches two cancer treatment trials
14 May 2024 11:42
(Sharecast News) - Hutchmed China announced the start of two significant clinical trials on Tuesday, aimed at addressing critical unmet needs in cancer treatment.
-
Hutchmed China to make several presentations at cancer research meeting
5 April 2024 11:54
(Sharecast News) - Hutchmed China announced the upcoming presentation of new and updated data from various studies featuring compounds it had discovered on Friday, at the American Association of Cancer...
-
Hutchmed endometrial cancer treatment gets priority review in China
2 April 2024 12:11
(Sharecast News) - Hutchmed China announced the acceptance and granting of priority review by the China National Medical Products Administration (NMPA) for a new drug application combining fruquintinib and...
-
Hutchmed cancer treatment indication accepted for review in China
28 March 2024 13:02
(Sharecast News) - Hutchmed China announced a significant milestone in its cancer treatment work on Thursday, with the supplemental new drug application (sNDA) for savolitinib had been accepted for review by...
-
Hutchmed partner Inmagene exercises options over two drug candidates
2 February 2024 09:42
(Sharecast News) - Hutchmed China announced on Friday that Inmagene Biopharmaceuticals has exercised options to licence two drug candidates, IMG-007 and IMG-004, as part of their strategic partnership.
-
Hutchmed's 'Elunate' approved under new Hong Kong rules
30 January 2024 10:32
(Sharecast News) - Hutchmed China announced the approval of its drug 'Elunate', or fruquintinib, by the Pharmacy and Poisons Board of Hong Kong on Tuesday, for the treatment of adult patients with...
-
Hutchmed application for thrombocytopenia treatment accepted in China
11 January 2024 11:11
(Sharecast News) - Hutchmed China announced on Thursday that the new drug application (NDA) for sovleplenib, an oral inhibitor targeting spleen tyrosine kinase (Syk), had been accepted for review and granted...
-
Hutchmed completes trial enrolment, keeps drugs on China funding list
13 December 2023 12:20
(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs on the National Reimbursement Drug List (NRDL) in China.
-
Hutchmed completes trial enrolment, keeps drugs on China funding list
13 December 2023 12:20
(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs on the National Reimbursement Drug List (NRDL) in China.
Company announcements Announcements
No company announcements about Hutchmed (China) Limited ORD USD0.10 were found.
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.